Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities
Abstract Background Lefamulin, a first-in-class pleuromutilin antibiotic approved for intravenous and oral use in adults with community-acquired bacterial pneumonia (CABP), was noninferior to moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) 1 intravenous-to-oral switch study and the...
Main Authors: | Thomas M. File, Elizabeth Alexander, Lisa Goldberg, Anita F. Das, Christian Sandrock, Susanne Paukner, Gregory J. Moran |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12890-021-01472-z |
Similar Items
-
Lefamulin. Comment on: “Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. <i>Microorganisms</i>, 2019, <i>7</i>, 270”
by: Despoina Koulenti, et al.
Published: (2019-09-01) -
In vitro Activity of Lefamulin Against the Common Respiratory Pathogens Isolated From Mainland China During 2017–2019
by: Shi Wu, et al.
Published: (2020-09-01) -
Antibacterial Activity and Pharmacokinetic Profile of a Promising Antibacterial Agent: 22-(2-Amino-phenylsulfanyl)-22-Deoxypleuromutilin
by: Xiangyi Zuo, et al.
Published: (2020-02-01) -
Synthesis and Biological Activity Evaluation of Novel Heterocyclic Pleuromutilin Derivatives
by: Yunpeng Yi, et al.
Published: (2017-06-01) -
Insights into the Classical Genetics of Clitopilus passeckerianus – the Pleuromutilin Producing Mushroom
by: Kate M. J. de Mattos-Shipley, et al.
Published: (2017-06-01)